dehydro-aripiprazole

Dehydro-aripiprazole is an active metabolite of the atypical antipsychotic drug aripiprazole. It is formed in the liver primarily by the cytochrome P450 enzymes CYP3A4 and CYP2D6. Dehydro-aripiprazole exhibits a pharmacological profile similar to aripiprazole, acting as a partial agonist at dopamine D2 and D3 receptors, and showing affinity for serotonin 5-HT1A, 5-HT2A, and 5-HT2B receptors. It contributes significantly to the overall antipsychotic activity of aripiprazole and has a longer elimination half-life than its parent compound. While it possesses drug-like properties and contributes to therapeutic effects, it is primarily recognized as a metabolite and is typically available for research purposes only, not as a standalone approved pharmaceutical drug.